SFE Investment Counsel Increases Holdings in Zoetis Inc. (NYSE:ZTS)

SFE Investment Counsel increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,851 shares of the company’s stock after acquiring an additional 55 shares during the period. SFE Investment Counsel’s holdings in Zoetis were worth $1,277,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. Alliancebernstein L.P. raised its position in Zoetis by 7.1% in the first quarter. Alliancebernstein L.P. now owns 17,823,733 shares of the company’s stock valued at $2,806,882,000 after purchasing an additional 1,178,470 shares during the period. Polen Capital Management LLC boosted its position in shares of Zoetis by 2.2% during the 1st quarter. Polen Capital Management LLC now owns 11,587,601 shares of the company’s stock worth $1,824,815,000 after acquiring an additional 244,701 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Zoetis by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,062,310 shares of the company’s stock worth $1,584,612,000 after acquiring an additional 912,551 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 0.7% in the 1st quarter. Geode Capital Management LLC now owns 7,585,607 shares of the company’s stock valued at $1,191,202,000 after purchasing an additional 55,793 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Zoetis by 4.1% in the 1st quarter. Northern Trust Corp now owns 5,817,979 shares of the company’s stock valued at $916,216,000 after purchasing an additional 228,477 shares during the last quarter. 89.53% of the stock is currently owned by institutional investors.

Shares of ZTS stock traded up $0.82 on Wednesday, hitting $204.37. The company’s stock had a trading volume of 16,145 shares, compared to its average volume of 1,790,607. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.37 and a quick ratio of 2.51. Zoetis Inc. has a fifty-two week low of $141.41 and a fifty-two week high of $210.10. The firm’s fifty day moving average price is $203.07 and its 200-day moving average price is $181.17. The stock has a market capitalization of $96.86 billion, a price-to-earnings ratio of 50.78, a P/E/G ratio of 3.31 and a beta of 0.64.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 5th. The company reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.11. Zoetis had a net margin of 25.76% and a return on equity of 53.87%. During the same quarter last year, the company earned $0.89 earnings per share. Analysts predict that Zoetis Inc. will post 4.53 EPS for the current fiscal year.

In other Zoetis news, Director Willie M. Reed sold 1,450 shares of Zoetis stock in a transaction dated Monday, August 23rd. The shares were sold at an average price of $207.10, for a total value of $300,295.00. Following the completion of the sale, the director now owns 5,964 shares in the company, valued at approximately $1,235,144.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 22,450 shares of Zoetis stock in a transaction dated Thursday, July 22nd. The stock was sold at an average price of $199.18, for a total transaction of $4,471,591.00. The disclosure for this sale can be found here. Insiders have sold 48,003 shares of company stock worth $9,711,854 over the last quarter. 0.17% of the stock is owned by company insiders.

ZTS has been the subject of a number of analyst reports. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $186.00 target price for the company in a research note on Tuesday, June 1st. Raymond James lowered Zoetis from an “outperform” rating to a “market perform” rating in a research note on Friday, July 16th. Barclays increased their target price on Zoetis from $208.00 to $235.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Cantor Fitzgerald increased their target price on Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 13th. Finally, Argus increased their target price on Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, August 25th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $199.08.

Zoetis Company Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

See Also: Basic Economics creates winners and losers

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.